Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TACTICAL: TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

NCT07302776 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT07302776
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07302776 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TACTICAL: TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Lead sponsor
Stanford University
Phase
Phase 1
Overall status
Recruiting
Start date
July 21, 2026
Completion date
February 29, 2028
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml), chronic myeloid leukemia (cml), chronic myelomonocytic leukemia (cmml), gvhd, hematopoietic cell transplantation (hct), myelodysplastic syndromes, myelofibrosis (mf)